# Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early Nephropathy

> **NCT00157508** · PHASE2 · TERMINATED · sponsor: **Mario Negri Institute for Pharmacological Research** · enrollment: 13 (—)

## Conditions studied

- Type 2 Diabetes
- Early Nephropathy

## Interventions

- **DRUG:** nitroaspirin

## Key facts

- **NCT ID:** NCT00157508
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-03
- **Primary completion:** —
- **Final completion:** 2004-08
- **Target enrollment:** 13 (—)
- **Last updated:** 2015-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00157508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00157508, "Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early Nephropathy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00157508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*